News
Article
Author(s):
ICYMI, this week we had articles about KT-474 efficacy in atopic dermatitis and hidradenitis suppurativa, endoscopic thoracic sympathectomy surgery for hyperhidrosis, and new data on rademikibart for atopic dermatitis.
Ama Alexis, MD, shared the importance of recognizing diverse presentations of atopic dermatitis at the American College of Allergy, Asthma and Immunology (ACAAI) 2023 Annual Scientific Meeting.
This week’s collection of the latest dermatologic studies covers the relationship between melanoma pigmentation and inflammatory cytokines, the negative use of topical nystatin for tinea infections, the association between psoriasis and schizophrenia, and the association between pediatric atopic dermatitis and cardiovascular risk factors.
Jared Gollob, MD, Chief Medical Officer of Kymera Therapeutics, spoke with Dermatology Times to discuss these trial results.
Atoosa Kourosh, MD, MPH, delves into opportunities for allergists and dermatologists to collaborate, her approach to cases, and patient resources.
Immunotherapies, including PD-1 checkpoint inhibitors such as nivolumab, have improved the treatment options for patients with advanced melanoma.
The newest source of growth factors is from donor tissue.
Andrew F. Alexis, MD, MPH, shared insights into using JAK inhibitors as part of the treatment revolution in atopic dermatitis at the American College of Allergy, Asthma & Immunology Annual Scientific Meeting.
Experts discuss enhancing patient outcomes, topical formulations and epidermal barrier dysfunction, and more.
From the November cover: Raj Chovatiya, MD, PhD, and Lawrence Eichenfield, MD, shared their insights and key treatment pearls into atopic dermatitis management for adults and children.
Patient Cole Villaflor, his mother, and Michael Levy, MD, PhD, provide insights into Cole’s hyperhidrosis diagnosis and subsequent endoscopic thoracic sympathectomy surgery.
Patients with AD and a comorbid allergic condition achieved the same efficacy endpoints as patients without allergic conditions in a study.
Connect Biopharma announced positive long-term data from its China pivotal trial.
One notable change: CVS Caremark has removed the Humira biosimilar Amjevita and now prefers Hyrimoz and an unbranded biosimilar.
Because of the chronic inflammatory state of psoriasis and the immunosuppression produced by some systemic medications, patients with psoriasis may have an increased risk of lymphoma and nonmelanoma skin cancer.
Members of Dermatology Times’ Editorial Advisory Board share their perspectives on the most meaningful innovations of the year this Thanksgiving Day.
Click here to answer this week's poll for Hyperhidrosis Awareness Month.
The study found that white patients were offered access to patient portals more frequently than Black or Hispanic patients.
To stay up-to-date with the latest dermatology news, sign up to receive our eNewsletters.